logo-loader
viewLexaria Bioscience Corp.

Full interview: Lexaria BioScience CEO releases letter to shareholders as company looks for big 2020

Lexaria BioScience (CSE:LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive on Skype to discuss his letter to shareholders to start 2020. Bunka talked about some of the things he addressed in the letter including success in 2019 and what is head in 2020.

Bunka also talked about the capital markets and what he sees as an optional path for Lexaria in 2020. 
 

Quick facts: Lexaria Bioscience Corp.

Price: 0.61 CAD

CSE:LXX
Market: CSE
Market Cap: $49.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexaria Bioscience and Cannadips CEO’s discuss key point of...

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California. Bunka telling Proactive...

4 days, 16 hours ago

2 min read